TLN-372
/ Treeline Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 03, 2025
Treeline Announces First Clinical Trials and Secures $200M in Additional Funding
(Businesswire)
- "Treeline Biosciences (or Treeline) today announced the initiation of Phase 1 trials for two internally discovered programs, TLN-121 and TLN-372, and a third in-licensed program, TLN-254."
Financing • Trial status • Lymphoma • Solid Tumor
October 03, 2025
TLN-372 in Advanced KRAS Mutant Solid Tumors
(clinicaltrials.gov)
- P1 | N=240 | Recruiting | Sponsor: Treeline Biosciences, Inc.
New P1 trial • Oncology • Solid Tumor • KRAS
1 to 2
Of
2
Go to page
1